Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 134

1.

A prospective overview of the essential requirements in molecular modeling for nanomedicine design.

Kumar P, Khan RA, Choonara YE, Pillay V.

Future Med Chem. 2013 May;5(8):929-46. doi: 10.4155/fmc.13.67. Review.

PMID:
23682569
2.

Nanotechnology and nanomedicine: going small means aiming big.

Teli MK, Mutalik S, Rajanikant GK.

Curr Pharm Des. 2010 Jun;16(16):1882-92. Review.

PMID:
20222866
3.

Targeted nanoparticle-based drug delivery and diagnosis.

Emerich DF, Thanos CG.

J Drug Target. 2007 Apr;15(3):163-83. Review.

PMID:
17454354
4.

Characterization of nanoparticles for therapeutics.

Hall JB, Dobrovolskaia MA, Patri AK, McNeil SE.

Nanomedicine (Lond). 2007 Dec;2(6):789-803. Review.

PMID:
18095846
5.

Nanomedicine opportunities for cardiovascular disease with perfluorocarbon nanoparticles.

Lanza GM, Winter PM, Caruthers SD, Hughes MS, Cyrus T, Marsh JN, Neubauer AM, Partlow KC, Wickline SA.

Nanomedicine (Lond). 2006 Oct;1(3):321-9. Review.

PMID:
17716162
6.

A perspective of nanotechnology in hypersensitivity reactions including drug allergy.

MontaƱez MI, Ruiz-Sanchez AJ, Perez-Inestrosa E.

Curr Opin Allergy Clin Immunol. 2010 Aug;10(4):297-302. doi: 10.1097/ACI.0b013e32833b1f17. Review.

PMID:
20485158
7.

Nanomedicine approaches in vascular disease: a review.

Gupta AS.

Nanomedicine. 2011 Dec;7(6):763-79. doi: 10.1016/j.nano.2011.04.001. Review.

PMID:
21601009
8.

The upcoming field of theranostic nanomedicine: an overview.

Prabhu P, Patravale V.

J Biomed Nanotechnol. 2012 Dec;8(6):859-82. Review.

PMID:
23029995
9.

Challenges in design of translational nanocarriers.

Sun Q, Radosz M, Shen Y.

J Control Release. 2012 Dec 10;164(2):156-69. doi: 10.1016/j.jconrel.2012.05.042. Review.

PMID:
22664472
10.

[Nanomedicine: application of nanotechnology in medicine. Opportunities in neuropsychiatry].

Szebeni J.

Neuropsychopharmacol Hung. 2011 Mar;13(1):15-24. Review. Hungarian.

11.

Nanomedicine for cancer: lipid-based nanostructures for drug delivery and monitoring.

Namiki Y, Fuchigami T, Tada N, Kawamura R, Matsunuma S, Kitamoto Y, Nakagawa M.

Acc Chem Res. 2011 Oct 18;44(10):1080-93. doi: 10.1021/ar200011r. Review.

PMID:
21786832
12.

Nanotechnology platforms and physiological challenges for cancer therapeutics.

Kim KY.

Nanomedicine. 2007 Jun;3(2):103-10. Review.

PMID:
17442621
13.

Emerging nanomedicine opportunities with perfluorocarbon nanoparticles.

Winter PM, Cai K, Caruthers SD, Wickline SA, Lanza GM.

Expert Rev Med Devices. 2007 Mar;4(2):137-45. Review.

PMID:
17359221
14.

Toward in silico approaches for investigating the activity of nanoparticles in therapeutic development.

Saliner AG, Poater A, Worth AP.

IDrugs. 2008 Oct;11(10):728-32. Review.

PMID:
18828072
15.

Application of nanotechnology in biomedicine.

Navalakhe RM, Nandedkar TD.

Indian J Exp Biol. 2007 Feb;45(2):160-5. Review.

PMID:
17375555
16.

First World Conference on Nanomedicine and Drug Delivery.

Elias E, Thomas S, George A, Sebastian M.

Ther Deliv. 2010 Aug;1(2):225-30.

PMID:
22816129
17.

Theranostic nanoparticles engineered for clinic and pharmaceutics.

Ma X, Zhao Y, Liang XJ.

Acc Chem Res. 2011 Oct 18;44(10):1114-22. doi: 10.1021/ar2000056. Review.

PMID:
21732606
18.

Nanomedicine: de novo design of nanodrugs.

Yang Z, Kang SG, Zhou R.

Nanoscale. 2014 Jan 21;6(2):663-77. doi: 10.1039/c3nr04535h. Review.

PMID:
24305636
19.

Combination therapy: opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines.

Greco F, Vicent MJ.

Adv Drug Deliv Rev. 2009 Nov 12;61(13):1203-13. doi: 10.1016/j.addr.2009.05.006. Review.

PMID:
19699247
20.

Nanotechnological applications in medicine.

Caruthers SD, Wickline SA, Lanza GM.

Curr Opin Biotechnol. 2007 Feb;18(1):26-30. Review.

PMID:
17254762

Supplemental Content

Support Center